Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC Patients

被引：9
|
作者：
Shi, Y. [1 ,2 ]
Xing, P. [1 ,2 ]
Han, X. [3 ,4 ]
Wang, S. [5 ]
Liu, Y. [1 ,2 ]
Liu, P. [1 ,2 ]
Li, J. [1 ,2 ]
Chang, L. [5 ]
Guan, Y. [5 ]
Zhang, Z. [1 ,2 ]
Wu, D. [1 ,2 ]
Yao, J. [1 ,2 ]
Xin, Y. [5 ]
机构：
[1] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Dept Clin Lab, Beijing, Peoples R China
[4] Peking Union Med Coll, Beijing 100021, Peoples R China
[5] Geneplus Beijing Inst, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
plasma ctDNA; non-small cell lung cancer; Resistance;
D O I：
10.1016/j.jtho.2018.08.875
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.13-18
引用
收藏
页码：S589 / S589
页数：1
相关论文
共 50 条
  • [1] Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients
    Chang, J.
    Hu, Z.
    Ji, D.
    Chuai, S.
    Shen, W.
    Cao, J.
    Wang, J.
    Wu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S671 - S671
  • [2] Track and treat in NSCLC (TATIN) - ctDNA guided treatment of early resistance to second-line osimertinib treatment in patients with EGFR mutation positive (EGFRm) NSCLC
    Jebbink, M.
    van der Wel, J. W. T.
    van den Broek, D.
    Boelens, M. C.
    Monkhorst, K.
    Ruiter, G.
    Burgers, S.
    Steinbusch, L.
    Baas, P.
    Kastelijn, L.
    van der Wall, E. E.
    Stellingwerf, M.
    Smit, E. F. F.
    de Langen, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1202 - S1202
  • [3] Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC
    Cheng, Michael L.
    Lau, Christie J.
    Milan, Marina S. D.
    Supplee, Julianna G.
    Riess, Jonathan W.
    Bradbury, Penelope A.
    Janne, Pasi A.
    Oxnard, Geoffrey R.
    Paweletz, Cloud P.
    JCO PRECISION ONCOLOGY, 2021, 5 : 393 - 402
  • [4] A prospective observational multicenter study on osimertinib resistance using ctDNA analysis in EGFR-mutated NSCLC
    Osuga, Mitsuo
    Tamiya, Akihiro
    Harada, Daijiro
    Mizumori, Yasuyuki
    Isa, Shunichi
    Taniguchi, Yoshihiko
    Nakamura, Keiichi
    Shinohara, Tsutomu
    Yanai, Hidetoshi
    Nakatomi, Katsumi
    Oki, Masahide
    Mori, Masahide
    Kuwako, Tomohito
    Yamazaki, Koji
    Ando, Masahiko
    Koh, Yasuhiro
    CANCER SCIENCE, 2025, 116 : 330 - 330
  • [5] Prediction of PFS using a dynamic assessment of ctDNA in patients with EGFR mutated NSCLC with osimertinib therapy
    Moiseenko, F.
    Stepanova, M.
    Zhabina, A.
    Myslik, A.
    Klimenko, V.
    Rysev, N.
    Artemieva, E.
    Shelekhova, K.
    Bogdanov, A.
    Volkov, N.
    Moiseenko, V.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Circulating tumor DNA analysis for osimertinib resistance Chinese NSCLC patients.
    Gu, Weiguang
    Li, Yong
    Hong, Hongxi
    Liu, Bai
    Wang, Aodi
    Liu, Wenjin
    Mu, Shuo
    Yao, Ming
    Wang, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Association of ctDNA quantification with prognosis and early prediction of response to first-line osimertinib in NSCLC patients
    Denis, M. G.
    Herbreteau, G.
    Charpentier, S.
    Vallee, A.
    Cadranel, J.
    Valette, C. Audigier
    Tomasini, P.
    Masson, P.
    Pons-Tostivint, E.
    Gervais, R.
    Girard, N.
    Cortot, A.
    Molinier, O.
    Monnet, I.
    Marcq, M.
    Urban, T.
    Moro-Sibilot, D.
    Lena, H.
    Sagan, C.
    Bennouna, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1035 - S1035
  • [8] Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
    Gray, J.
    Okamoto, I.
    Sriuranpong, V.
    Vansteenkiste, J.
    Imamura, F.
    Lee, J. S.
    Pang, Y.
    Cobo, M.
    Kasahara, K.
    Hodge, R.
    Lentrichia, B.
    Dearden, S.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1755
  • [9] Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC
    Kim, C.
    Xi, L.
    Cultraro, C.
    Wei, F.
    Cheng, J.
    Shafiei, A.
    Pham, T.
    Roper, N.
    Akoth, E.
    Strom, C.
    Tu, M.
    Liao, W.
    Chia, D.
    Morris, C.
    Rajan, A.
    Bagheri, M.
    Jones, G.
    Wong, D.
    Raffeld, M.
    Guha, U.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S366 - S366
  • [10] Longitudinal disease monitoring with ctDNA during osimertinib treatment in EGFR T790M positive NSCLC patients (WJOG8815L)
    Kato, Terufumi
    Sakai, Kazuko
    Takahama, Takayuki
    Shimokawa, Mototsugu
    Azuma, Koichi
    Takeda, Masayuki
    Okamoto, Isamu
    Daga, Haruko
    Teraoka, Shunsuke
    Takahashi, Toshiaki
    Ohira, Tatsuo
    Yokoyama, Toshihide
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    ANNALS OF ONCOLOGY, 2021, 32 : S323 - S323
12345